Physiologically based pharmacokinetic (PBPK) models for the intestine, comprising of different flow rates perfusing the enterocyte region, were revisited for appraisal of flow affects on the intestinal availability (F I ) and, in turn, the systemic availability (F sys ) and intestinal versus liver contribution to the first-pass effect during oral drug absorption. The traditional model (TM), segregated flow model (SFM), and effective flow (Q Gut ) model stipulate that 1.0, ϳ0.05 to 0.3, and <0.484؋ of the total intestinal flow, respectively, reach the enterocyte region that houses metabolically active and transporter-enriched enterocytes. The fractional flow rate to the enterocyte region (f Q ), when examined under varying experimental conditions, was found to range from 0.024 to 0.2 for the SFM and 0.065 to 0.43 for the Q Gut model. Appraisal of these flow intestinal models, when used in combination with whole-body PBPK models, showed the ranking as SFM < Q Gut model < TM in the description of F I , and the same ranking existed for the contribution of the intestine to first-pass removal. However, the ranking for the predicted contribution of hepatic metabolism, when present, to firstpass removal was the opposite: SFM > Q Gut model > TM. The findings suggest that the f Q value strongly influences the rate of intestinal metabolism (F I and F sys ) and indirectly affects the rate of liver metabolism due to substrate sparing effect. Thus, the f Q value in the intestinal flow models pose serious implications on the interpretation of data on the first-pass effect and oral absorption of drugs.
Introduction
Compartmental models are no longer adequate to address effects of permeability barriers Pang, 1986, 1987) , intestinal and liver transporters and enzymes (Suzuki and Sugiyama, 2000a,b) , and sequential metabolism within the intestine and liver (Pang and Gillette, 1979; Sun and Pang, 2010) during oral drug absorption (for reviews, see Pang, 2003; Pang et al., 2008; Fan et al., 2010; Pang and Durk, 2010; Chow and Pang, 2013) . These aspects are especially pertinent when intestinal metabolic activity is substantial relative to that in the liver, and when different extents of induction/inhibition of intestinal and hepatic enzymes or transporters are the result of treatment with the culprit compound, which usually shows a higher induction/inhibition effect with oral administration (Fromm et al., 1996; Paine et al., 1996; Thummel et al., 1996; Eeckhoudt et al., 2002; Mouly et al., 2002; Fang and Zhang, 2010; Liu et al., 2010; Lledó-García et al., 2011; Zhu et al., 2011) .
Over the past decade, there have been exciting advances made toward the development of physiologically relevant pharmacokinetic (PBPK) intestinal models to interrelate intestinal transporters, enzymes, and blood flow in the appraisal of their influence on intestinal (F I ), liver (F H ), and oral systemic (F sys or F abs F I F H ) availability. In this commentary, we revisited several physiologically based intestinal models that are associated with differential flow patterns: the traditional model (TM), in which the entire intestinal flow perfuses the enterocyte region; the segregated flow model (SFM), in which a low enterocyte flow (Q en ) perfuses the enterocyte region (fractional flow, f Q or Q en /Q PV is Յ0.3) (Cong et al., 2000) ; and the Q Gut model, in which the effective flow Q Gut that perfuses the enterocyte region is at best half the intestinal flow and close in value to the villous flow (Q villi ) (Yang et al., 2006 (Yang et al., , 2007 Gertz et al., 2010) . These three intestinal models are viewed as competent to describe the immediate removal of the formed metabolite by excretion or sequential metabolism within the intestine and/or further processing by liver, for drugs and metabolites exhibiting varying permeability properties (Cong et al., 2000; Yang et al., 2006 Yang et al., , 2007 Gertz et al., 2010; Sun and Pang, 2010) . The models are more prepared to supply mechanistic insight into the pharmacokinetics of drugs and their metabolites and allow inclusion of transporters into different organ components (apical or basolateral membranes) to discriminate between the permeability properties of the drug and its formed metabolite in permitting or delimiting influx and efflux in drug and metabolite processing (Pang et al., 2008; Darwich et al., 2010; Galetin et al., 2010; Gertz et al., 2010; Rowland Yeo et al., 2010; Chow and Pang, 2013) . By virtue of inclusion of transport and eliminatory events, these physiologically based models are able to more accurately describe the net appearance of the formed metabolite into the systemic circulation, because metabolite levels can be drastically reduced as a result of sequential metabolism (Pang and Gillette, 1979) .
Intestinal PBPK models have been incorporated into whole body PBPK modeling. The semi-PBPK model proposed by Hall and colleagues (Quinney et al., 2008; Zhang et al., 2009; Quinney et al., 2010) resembles the TM-PBPK and features the intestine and liver tissues separately while minimizing the number of other tissues involved, retaining characteristics of the intestine and liver to describe metabolism, transport, and binding. The semi-PBPK model has been used to describe midazolam inhibition by intestinal and hepatically formed metabolites, N-desmethyldiltiazem from diltiazem in humans (Zhang et al., 2009) , and hydroxyitraconazole from itraconazole in rats (Quinney et al., 2008) , and in the estimation of the contribution of the intestine (ϳ30 -40%) in furamidine formation from pafuramidine in a prodrug-drug relationship in rats, then humans (Yan et al., 2012) . Chow et al. (2011) used the combined TM-PBPK and SFM-PBPK models to predict the 1.8-and 2.6-fold induction of brain and kidney P-glycoprotein (P-gp) protein expression with the vitamin D receptor ligand, 1␣,25-dihydroxyvitamin D 3 , respectively, and demonstrated a superior fit with the SFM-PBPK model in explaining the P-gp-mediated excretion of digoxin. In the perfused rat intestine preparation in which the intestine is the only eliminating tissue, the SFM was found to be superior to the TM in describing morphine glucuronidation (Cong et al., 2000) and digoxin excretion by the P-glycoprotein under induced and noninduced states (Liu et al., 2006) . In this commentary, we appraised how these intestinal flow models differed by examining the effects of enterocytic flow on F I and, in turn, F sys and the extents of intestinal and liver first-pass removal with use of simulations.
Theoretical: The Intestinal Flow Models
The TM and SFM. Historically, the TM and SFM were first introduced by Cong et al. (2000) to offer an explanation of the higher extent of intestinal metabolism of erythromycin (Lown et al., 1995) and midazolam in humans, and enalapril hydrolysis (Pang et al., 1985) and morphine glucuronidation in the vascularly perfused rat intestine preparation between oral (po) versus intravenous (iv) dosing of drugs. Both models describe the effects of protein binding, enzymes for parallel and sequential pathways, and passive diffusion and/or transporter-driven permeation in metabolically and transport-competent enterocytes (Cong et al., 2000) . In this model, one or more metabolic pathways, denoted as the metabolic intrinsic clearances, CL int,met1,I and CL int,met2,I , for the intestine may exist for precursor drug (P), and, similarly, CL int,met1,H and CL int,met2,H denote parallel metabolic pathways for the liver (Fig. 1) . Drug secretion is represented by the CL int,sec,I for the intestinal secretion intrinsic clearance and CL int,sec,H for the liver biliary intrinsic clearance. Figure 1A denotes intestinal removal only, whereas Fig. 1B denotes both intestinal and liver removal; there is no elimination from other organs and tissues, which are lumped as highly and poorly perfused tissues. The influx and efflux clearances are denoted as CL d1 , CL d2 , CL d3 , and CL d4 for the intestine (Fig. 1B , superscript I) and liver (Fig. 1B, superscript H) ; the unbound fractions in blood, intestine, and liver are denoted as f B , f I , and f H , respectively (although not shown in Fig. 1 for the sake of simplification). The single, significant difference between the TM and SFM is the flow pattern for perfusion of tissue regions of the small intestine. The SFM emphasizes a low flow (f Q Ϸ 0.05-0.3ϫ total intestinal flow) that perfuses the enterocyte region, and the remaining flow [(1-f Q )Q PV ] is shunted to the serosal or nonactive region (Fig. 1) . This segregated flow pattern contrasts with the TM that describes the entire flow being able to reach the enterocyte or the total intestinal tissue, that is, f Q ϭ 1 (Cong et al., 2000) .
Explicit solutions for the area under the curves (AUCs) for the TMand SFM-PBPK models that feature the intestine as the only eliminating organ (Fig. 1A) were provided by Pang, (2009, 2010 
and
In eqs. 1 and 2, the f B term appears next to CL d1 I . It is also recognized that tissue binding effects are apparently nonoperative because the f I term cancels out in both the numerator and denominator. The difference in flow between the TM and SFM is denoted by f Q , the fraction of Q PV that perfuses the enterocyte region; for TM, f Q ϭ 1, whereas for SFM, f Q ϭ 0.05 to 0.3. The flow term is absent for AUC po but present in AUC iv . Accordingly, the F I and F sys is as follows:
Likewise, the AUCs for the TM-and SFM-PBPK models that feature both the intestine and liver as eliminating organs (Fig. 1B) have been solved (Sun and Pang, 2010) , and their ratio, after consideration given to protein binding, is as follows:
out in both the numerator and denominator. In eq. 4, the f B term appears next to the influx clearances for the intestine and liver, CL d1 I and CL d1 H . Increases in f B would generally lower F I according to eqs. 3 and 4.
These solutions for F I (eqs. 3 and 4) revealed the blunting effect due to drug reabsorption, or the factor (1-F abs ), where F abs or fraction absorbed is k a /(k a ϩ k g ) [where k g is the luminal degradation constant that comprises gastrointestinal transit and degradation] (Lin et al., 1999; Pang, 2009, 2010) . The F abs term has been reported to be highly correlated to the permeability of drug, P app (Zhu et al., 2002; Corti et al., 2006; Kadono et al., 2010) . Apical secretion mediated via the CL int,sec,I was nullified when the fraction absorbed ϳ1, rendering the conclusion that F I is affected more by CL int,met,I and not so much by CL int,sec,I Pang, 2009, 2010; Chow and Pang, 2013) . As emphasized for the SFM, the partial flow suggests a bypass of enterocytes for drugs entering the intestinal tissue from the systemic circulation, whereas by design, drug given orally necessitates passage of the entire absorbed amount through the enterocyte region. This scenario would lead to a greater extent of intestinal removal for the drug the liver and other lumped compartments (highly perfused, poorly perfused) being connected to the intestine model (TM and SFM), depicting the intestine (A) and intestine and liver (B) as the eliminating tissue(s)/organ(s). The intestine subcompartments are as follows: for TM, subscripts int and intB denote intestinal tissue and intestinal blood, respectively; for SFM, subscripts en and enB denote enterocyte and enterocyte blood, respectively; s and sB denote serosal tissue and serosal blood, respectively. For the liver, subscripts L and LB represent liver tissue and liver blood, respectively; subscript R denotes the reservoir or blood compartment. For TM, the intestine represents a well mixed enterocyte region and receives the entire intestinal blood flow, Q I or Q PV . For SFM, the intestinal blood flow is segregated to perfuse the enterocyte and serosal regions; the flow to the enterocyte region is denoted as f Q Q PV , and the serosal region, (1-f Q )Q PV . At the basolateral membrane, the drug influx and efflux clearances into or out of the intestine or enterocyte are characterized by the transport clearance parameters CL d1 I and CL d2 I , respectively. For SFM, additional influx and efflux clearance into or out of the serosal tissue compartment are characterized by the transport clearance parameters, CL d3 I and CL d4 I . The liver receives blood from hepatic blood artery (Q HA ) arising from the blood compartment and venous flow, Q PV , from the intestine; the summed blood flow exits the liver as Q H . The influx and efflux clearances of the drug into or out of the liver are CL d1 H and CL d2 H , respectively. Intrinsic metabolic clearance of parent drug (P) to form the primary metabolites in the intestine are denoted as CL int,met1,I and CL int,met2,I , and those in liver are CL int,met1,H and CL int,met2,H ; the intestine and liver secrete P out via secretory intrinsic clearances, CL int,sec,I and CL int,sec,H , respectively. The bile flow rate is denoted as Q bile . Drug administrated orally (solution form) is administered into the lumen and may be either absorbed into intestine with the rate constant, k a , or degraded in lumen by the rate constant, k g ; drug given intravenously directly enters the blood compartment. given orally versus when the drug is given intravenously (Cong et al., 2000) , rendering "route-dependent intestinal removal."
The Q Gut Model. Yang et al. (2007) constructed the "Q Gut model" based on an effective flow, Q Gut , to the enterocyte region, by relating this effective Q Gut to the intestinal availability, F I , or F G in their terminology. The equation for F I is based analogously to the equation for hepatic availability (F H ), according to the well stirred liver model (Pang and Rowland, 1977) , where f I is the unbound fraction of drug in intestinal tissue and CL int,I , the total, intestinal intrinsic clearance that encompasses both secretion and metabolism.
The Q Gut is a hybrid term derived from the actual Q villi [18 l/h or 300 ml/min , representing ϳ48.4% of the total intestinal flow (assumed to equal the portal venous flow or Q PV , ϳ 620 ml/min) (Valentin, 2002; Yang et al., 2006 Yang et al., , 2007 ] and drug permeability clearance (CL perm ), a parameter that is normally estimated as the area x effective permeability (P eff ) assessed from perfused (human) jejunal studies, from Caco-2 cell P app , or based on physicochemical data such as hydrogen bond donors and polar surface area. The Q Gut value of midazolam, a drug with high apparent permeability, was estimated to be 16.6 l/h, a value that is 92% of the value of Q villi .
For a drug that is highly permeable, CL perm Ͼ Ͼ Q villi , it may be deduced that Q Gut Х Q villi .
Upon substitution of eq. 6 into eq. 5, the following is obtained:
As originally conceived by Yang et al. (2007) , the CL perm term stands collectively for CL d1 I and CL d2 I but should be replaced appropriately by either CL d1 I or CL d2 I . Upon comparison of eq. 7 with eq. 3, the CL perm terms for the Q Gut model could now be assigned. By analogy to eq. 3, it is further recognized that f I CL int,I is equivalent to the composite term, f I [CL int,met1,I ϩ CL int,met2,I ϩ (1-F abs )CL int,sec,I )]. The term f I CL int,I , in the Q Gut model which represents the summed unbound metabolic and secretory intrinsic clearances, fails to consider the intestinal secretion followed by reabsorption of the secreted material in the lumen. Upon consideration of all these missed events:
eq. 8 is obtained for the Q Gut model, in an equivalent format as that for the TM and SFM (eq. 3). Similarities are seen between the SFM/TM and the Q Gut model. The f Q Q PV term for the SFM is equivalent to the Q villi term of the Q Gut model (300 ml/min), which describes a partial flow (f Q ϭ 0.484) perfusing the enterocyte region.
Results

Comparison of f Q .
A proper comparison of these models has not been made in any rigorous fashion, especially in regard to f Q on F I . The starting point of the comparison is f Q , being of a low value (ϳ0.05-0.3) for the SFM, ϳ0.5 (Q villi /Q PV ϭ 0.484) for the Q Gut model, and highest (1.0) for the TM. We feel that the f Q term could serve as an important variable for selection of the most appropriate model to best describe the intestine. Upon perusal of the literature, estimates of Q Gut according to eq. 2 for various drugs range from 2.4, 5.7, 8.6, to 16.6 l/h, corresponding to 6.5 to 43% of the total intestinal flow, with good predictions for midazolam but poor estimation of F I (or F G ) for saquinavir in vivo . Some of these f Q values for the Q Gut model are higher than the f Q values of 0.07, 0.024, and 0.2 estimated from fits of the SFM to the data on benzoic acid (Cong et al., 2001) , morphine (Cong et al., 2000) , and digoxin (Liu et al., 2006) , respectively, from vascularly perfused rat small intestine preparations. For digoxin, which is mainly excreted unchanged in the mouse in vivo, a value of 0.16 was found for f Q (Chow et al., 2011) . The f Q terms, whether for the SFM or for Q Gut model, are less than unity Chow and Pang, 2013) , with f Q values being higher (Ͼ0.3) for the Q Gut model. Values of f Q for the SFM are lower and correspond better with published evidence that suggests segregated flows for the small intestine, and that a small fraction of flow (5-30%) perfuses the active, mucosal region (Granger et al., 1980) . Simulation of F I . Equation 1 for the TM and SFM, which consider the intestine as the only eliminating organ, lacks any of the flow terms and suggests that AUC po is identical among the TM, Q Gut model, and SFM, whereas the AUC iv intended for the TM/SFM (eq. 2) consists of the flow term, f Q Q PV for SFM and TM, and Q villi for the Q Gut model, by analogy. Thus, different AUC iv values for the Q Gut model and the SFM result when the flow term is replaced by the appropriate flow rate, f Q Q PV or Q villi . Because the rate of intestinal metabolism is dependent on the flow rate for delivery of substrate, it may be concluded that, when a smaller flow reaches the enterocyte region, a smaller intestinal removal rate results with systemic delivery. The ranking of the intestinal removal rate is SFM Ͻ Q Gut model Ͻ TM after intravenous dosing. The lower flow rate stipulated by the SFM in bringing the substrate into enterocyte region yields a higher AUC iv (ranking for AUC iv : SFM Ͼ Q Gut model Ͼ TM) and consequently a lower F I for the SFM compared with the Q Gut model and TM for given CL int,met,I values. This view is supported by the simulations (Fig. 2A) . The ranking of F I was SFM Ͻ Q Gut model Ͻ TM.
It is further observed that the solutions for F I are identical for the scenario in which the intestine is the only eliminating organ (eq. 3) and when the intestine and liver are both eliminating organs (eq. 4). These patterns for F I ( Fig. 2A) are translated into F sys for any given F H (ϭ 0.1, 0.5, or 0.9; Fig. 2B ). Again, the simulated patterns are consistent with the view that a decreased intestinal extraction ratio is accompanied by an increase in mesenteric flow (Chen and Pang, 1997; Chalasani et al., 2001; Yang et al., 2007; Chow and Pang, 2013) ; the lower intestinal removal rate due to lower enterocytic flows would result in higher hepatic processing, as observed experimentally by Chen and Pang (1997) .
Changing CL d1 I or CL d2 I on F I . When we further examined the effects of the basolateral influx (CL d1 I ) or efflux (CL d2 I ) transport clearances for drugs that exhibit varying degrees of absorption (described by F abs ϭ 0.1, 0.5, and 1.0), all models show that F I is attenuated when CL d1 I is increased or when CL d2 I is decreased (Fig. 3) . Increasing the influx basolateral clearance (CL d1 I ) from low to high (Fig. 3) ], higher F I values are attained due to ability of the influxed drug to escape intestinal enzymes intracellularly. The f Q effects from the flow models are apparent again with the simulations, and the ranking for F I values is SFM Ͻ Q Gut model Ͻ TM (Fig. 3) .
Contributions from Intestine and Liver to First-Pass Effect. To assess the contributions from the intestine versus the liver in first-pass removal among these flow-intestinal models, we further simulated the rates predicted from the mass equations shown below (eqs. 9 and 10) that describe the rates of intestinal (v I ) and hepatic (v H ) removal. For estimation of the rates, there exists the need to define the flowaveraged portal venous concentration, C PV , to account for the partial flow entering the enterocyte region, and for accurate prediction of the intestinal removal rate, v I .
Here, E is the extraction ratio for the intestine or liver that equals (1-F), and C A is the arterial concentration. The fractional contributions by the intestine and liver may now be calculated. The fractional contribution by intestine to the first-pass effect is as follows: (12) and the fractional contribution by liver to the first-pass effect is as follows:
FIG. 2. Effects of changing CL int,met1,I (e.g., induction or inhibition of enzymes) on F I according to the TM, Q Gut model, and SFM with eq. 4 (A) and F sys with the F I values shown in A under varying conditions of F H ϭ 0.1, 0.5, and 0.9 (B). In this simulation, CL int,sec,I was set as 200 ml/min; Q PV ϭ 620 ml/min; f Q ϭ 1.0 (TM), or 0.484 (Q Gut model) and 0.1 (SFM); F abs ϭ 0.1, 0.5, or 0.9; CL int,met2,I ϭ 0; CL d1 I ϭ CL d2 I ϭ 20ϫ Q PV , denoting a highly permeable drug.
Q villi replaces f Q Q PV, in eqs. 9, 10, 12, and 13 for the Q Gut model, with f Q ϭ 0.484. Again, substitution of f Q (ϭ 1, 0.484, and 0.1 for TM, Q Gut model, and SFM, respectively) embedded in F I or E I (eq. 3) yields the corresponding fractional removal estimates. Accordingly, the lower intestinal removal rate (v I ) predicted by the SFM due to the reduced flow rate results in a correspondingly higher contribution by the liver due to the substrate sparing effect of the intestine (Fig. 4) . Whereas for TM, the greater intestinal contribution in removing the drug leads to a lesser removal contribution by the liver due to a substrate depleting effect of the intestine (Fig. 4) . Predictions from the Q Gut model on the intestinal and liver contributions to first-pass removal fall in between those for the SFM and TM, and the patterns are similar when F abs ϭ 0.1 or 0.9 (Fig. 4) .
Again, the predictions reveal that the f Q values in different intestinal models affect the contributions of the intestine and liver in the first-pass effect. For any given CL int,met1,I , this difference translates to ranking for the intestinal contribution to the first-pass effect as TM Ͼ Q Gut Ͼ SFM, and for the liver, the ranking is TM Ͻ Q Gut Ͻ SFM. These opposite trends in intestinal versus hepatic contributions to first-pass have been discussed by Xu et al. (1989) and Chen and Pang (1997) , who attributed their observations to the anterior positioning of the intestine without recognizing the segregated flow effects. It must be commented that the effect of F abs is not apparent in altering the contributions of the intestine or liver in first-pass removal in these simulations; the F abs term affects only the reabsorption of the intestinally secreted drug (eqs. 3 and 4), which has been, for all intent and purpose, a minor pathway (CL int,sec,I ϭ 200 ml/min) relative to values of CL int,met1,I examined.
Effects of Binding. The mathematical manipulation reveals that tissue binding effects are canceled out because the unbound fraction terms in intestine (f I ) or liver (f H ) are absent in both the numerator and denominator. As seen from eqs. 3 and 4, only the f B term persists in the equations and is associated with the influx clearances, CL d1 , for the intestine and liver (superscripted I and H, respectively) . Upon changing f B at three sets of CL int,met1,I values for the various models (Fig. 5) , it could be seen that increased values of f B generally lower F I (Fig. 5) . Exceedingly similar patterns are observed for F abs ϭ 0.1 and 0.9.
Discussion
This examination reveals that f Q is the key issue in the prediction of F I and contribution of both the intestine and liver to first-pass removal. The Q Gut model is similar to the SFM in many respects, except that a higher limit exists for f Q . The simulations, based on the various f Q values, show that the predicted intestinal availability of the Q Gut model falls between those of the TM and SFM models under varying conditions of efflux and influx clearances (Fig. 3) . Decreased intestinal availabilities are expected FIG. 3 . Effects of varying basolateral transport clearances, CL d1 I and CL d2 I , on F I according to eq. 3, for drugs that are highly absorbed (F abs ϭ 0.9). For these simulations, CL int,sec,I is set as 200 ml/min; Q PV is set as 620 ml/min, and f Q ϭ 1.0 (for TM), or 0.484 (for Q Gut model) and 0.1 (for SFM). Values of CL d1 I and CL d2 I are altered from 1, 5, and 20ϫ Q PV . The value of CL int,met2,I , the intrinsic clearance for the alternate metabolic pathway, is set as 0.
with lower f Q values (Fig. 2) , and this effect contributes to a greater proportion of first-pass extraction by the liver, the posterior organ (Fig. 4) .
A major issue for the prediction of F I is the choice of the correct f Q value for intestinal models, especially for the Q Gut model. The problem that the intended Q Gut term is a hybrid function of Q villi and CL perm (as shown in eq. 7) could now be circumvented with use of eq. 8. Although literature reports for the Q Gut model suggest that f Q varies between 0.07 and 0.43, we suggest use of the unambiguous Q villi term or f Q Q PV (f Q ϭ 0.484) for the Q Gut model, with inclusion of the CL d1 I and CL d2 I terms in lieu of CL perm , in a format similar to those for the SFM and TM (eq. 8) to define the fractional flow and the transport intrinsic clearances. This revelation implies that the effective flow rate to the enterocyte region (f Q ϭ 0.484) for the Q Gut model is higher than that for the SFM. Another revelation is that f I CL int,I in Q Gut model falls short of the more comprehensive term, [CL int,met,I ϩ (1-F abs )CL int,sec,I ], in the prediction of F G (or F I in our terms). This may be another reason why poor prediction prevails for some drugs that are P-gp substrates . Indeed, improved estimation of P eff with use of a P-gp inhibitor seemed to improve the F I prediction of saquinavir (Gertz et al., 2011) . The need for f I in the equation for the Q Gut model is questionable because the term cancels out even when the binding effects of intestinal tissue on efflux, metabolism, or excretion are taken into consideration.
Other theoretical modeling that considers heterogeneity of transporters and enzymes along the length of the small intestine, as in the segmental traditional (STM) and segmental segregated flow (SSFM) models (counterparts of TM and SFM), has revealed that metabolic heterogeneity strongly affects F I (Tam et al., 2003) . Wu (2012) has recently commented, in a theoretical examination, that heterogeneity matters in predicting F sys after comparison of simulations from the TM-PBPK and SSFM-PBPK models on the systemic availability of the parent aglycone during the process of enterohepatic circulation of biliarily excreted glucuronides. The consideration of heterogeneity of transporters and enzymes on intestinal modeling in vivo surfaced much later, possibly due to the difficulty in obtaining population and length-averaged estimates on physiological dimensions of the lumen, surface area, flow, and enzymes and transporters in humans and animals (Badhan et al., 2009; Bruyère et al., 2010) . Other compartmental models, when coupled with a refined description on the linear transfer kinetics of state properties of the drug (unreleased or solid form, undissolved or aggregate form, and dissolved or solution form), physicochemical properties (pKa, solubility, particle size, particle density, and permeability), physiological properties (gastric emptying, intestinal transit rate, intestinal metabolism, and luminal transport), and dosage factors (dosage form and dose), in the gastrointestinal tract show much improved predictions of drug kinetics (Agoram et al., 2001; Hendriksen et al., 2003) , especially with inclusion of heterogeneity factors in the modeling (Bolger et al., 2009; Abuasal et al., 2012) . However, the ability of many of the present models to fully . The designated drug examples vary from being poorly to highly absorbed (F abs ϭ 0.1 and 0.9), the hepatic availability (F H ) of which vary from 0.1 to 0.9, Q HA ϭ 300 ml/min and CL d1 I ϭ CL d2 I ϭ 20ϫ Q PV , with an excretion component CL int,sec,I ϭ 200 ml/min and a nonexistent, alternate metabolic pathway (CL int,met2,I ϭ 0); the assigned flow rates were as follows: Q PV ϭ 620 ml/min; f Q ϭ 1.0 (TM) or 0.1 (or Q en /Q PV for SFM). Simulations for the Q Gut model (f Q ϭ 0.484) were intermediate of those for the SFM and TM. See text for details.
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at ASPET Journals on June 26, 2017 dmd.aspetjournals.org describe metabolite kinetics remains uncertain. We have noted that heterogeneity models such as the SSFM and STM (Tam et al., 2003) , whether necessary or not, are more pertinent in cases of enzyme heterogeneity among the segments. In absence of metabolism by the intestine, we found that the STM and SSFM perform as well as the TM and SFM, as found for studies on the absorption of benzoic acid (Cong et al., 2001 ) and digoxin absorption and efflux by P-gp (Liu et al., 2006) in the vascularly perfused intestine preparation. The presence of metabolite data is an absolute necessity for the discrimination between the SFM and TM.
It can be concluded that the designated flow rate to the enterocyte region of the intestine, defined according to the different intestinal flow models, strongly affects F I and F sys and the proportions of intestinal and liver in first-pass removal. With the solved equations for the AUCs, it is apparent that predictions on the interplay between intestine and hepatic transporters and enzymes are readily attainable Sun and Pang, 2010) . Key issues for proper intestinal modeling are the accurate definition of f Q and improved estimates of the transport clearances. The proper definition of f Q is of paramount importance, and this awaits use of sophisticated tools to properly estimate the enterocyte versus the total intestinal flow rate. Notwithstanding the deficiencies persisting in all of the mentioned models, it is rewarding to see how the theoretical refinement in intestinal modeling has advanced our activity and knowledge toward how transporter and enzyme heterogeneity as well as segregated flow patterns affect drug metabolism and excretion by the small intestine and liver in first-pass removal during oral drug absorption.
Authorship Contributions
Participated in research design: Pang and Chow.FIG. 5 . Effects of changing f B on F I according to the TM, Q Gut model, and SFM with eq. 3 at F abs ϭ 0. 1 (A) or 0.9 (B) at CL int,met1,I ϭ 100, 1000, or 2000 ml/min. In this simulation, CL int,sec,I is set as 200 ml/min; Q PV ϭ 620 ml/min; f Q ϭ 1.0 (TM), 0.484 (Q Gut model) or 0.1 (SFM); CL int,met2,I ϭ 0; CL d1 I ϭ CL d2 I ϭ 20ϫ Q PV , denoting a highly permeable drug. See text for details. 
